title: Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation.
abstract: BACKGROUND
  Dendritic cell (DC)-based vaccination has been investigated as immunotherapy for several types of cancer. A potential drawback to vaccination with autologous monocyte-derived DCs (MoDCs) could be that MoDCs from patients are functionally impaired. In case of androgen-independent prostate cancer (CaP), the cancer itself, diverse prior therapies, and the hormone manipulation may affect the immune system.
  
  
  METHODS
  MoDCs from patients suffering from androgen-independent CaP were generated according to a clinically applicable protocol to evaluate the phenotype, maturation capacity, migration, and T-cell stimulation of these cells compared with those generated from tumor-free donors.
  
  
  RESULTS
  MoDCs generated from CaP patients could be fully matured and efficiently migrated towards the chemokine CCL21. They had a strong potency to activate allogeneic CD4+ and CD8+ T-cells and to present antigens to specific CTL.
  
  
  CONCLUSIONS
  Our data suggest that MoDCs from patients with androgen-independent CaP are functionally intact and hence qualify as cellular vaccines for immunotherapy of advanced stage CaP.
authors.affiliation: Research Department, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
authors.forename: Ying
authors.initials: Y
authors.lastname: Waeckerle-Men
authors.forename: Edith Uetz-von
authors.initials: EU
authors.lastname: Allmen
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
authors.forename: Brendan J
authors.initials: BJ
authors.lastname: Classon
authors.forename: Elke
authors.initials: E
authors.lastname: Scandella
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Schmid
authors.forename: Burkhard
authors.initials: B
authors.lastname: Ludewig
authors.forename: Marcus
authors.initials: M
authors.lastname: Groettrup
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
mesh_terms: D000368:Aged; D000728:Androgens / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D002450:Cell Communication / Q000276:immunology; D002465:Cell Movement / Q000276:immunology*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000628:therapy
chemical_list: D000728:Androgens; D019496:Cancer Vaccines